298 related articles for article (PubMed ID: 35608753)
1. CRISPR-Based Genome-Editing Tools for Huntington's Disease Research and Therapy.
Qin Y; Li S; Li XJ; Yang S
Neurosci Bull; 2022 Nov; 38(11):1397-1408. PubMed ID: 35608753
[TBL] [Abstract][Full Text] [Related]
2. The potential of gene editing for Huntington's disease.
Duan W; Urani E; Mattson MP
Trends Neurosci; 2023 May; 46(5):365-376. PubMed ID: 36907678
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9 Mediated Therapeutic Approach in Huntington's Disease.
Alkanli SS; Alkanli N; Ay A; Albeniz I
Mol Neurobiol; 2023 Mar; 60(3):1486-1498. PubMed ID: 36482283
[TBL] [Abstract][Full Text] [Related]
4. Generation of New Isogenic Models of Huntington's Disease Using CRISPR-Cas9 Technology.
Dabrowska M; Ciolak A; Kozlowska E; Fiszer A; Olejniczak M
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32182692
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo.
Monteys AM; Ebanks SA; Keiser MS; Davidson BL
Mol Ther; 2017 Jan; 25(1):12-23. PubMed ID: 28129107
[TBL] [Abstract][Full Text] [Related]
6. Cas9-mediated replacement of expanded CAG repeats in a pig model of Huntington's disease.
Yan S; Zheng X; Lin Y; Li C; Liu Z; Li J; Tu Z; Zhao Y; Huang C; Chen Y; Li J; Song X; Han B; Wang W; Liang W; Lai L; Li XJ; Li S
Nat Biomed Eng; 2023 May; 7(5):629-646. PubMed ID: 36797418
[TBL] [Abstract][Full Text] [Related]
7. An RNA-targeting CRISPR-Cas13d system alleviates disease-related phenotypes in Huntington's disease models.
Morelli KH; Wu Q; Gosztyla ML; Liu H; Yao M; Zhang C; Chen J; Marina RJ; Lee K; Jones KL; Huang MY; Li A; Smith-Geater C; Thompson LM; Duan W; Yeo GW
Nat Neurosci; 2023 Jan; 26(1):27-38. PubMed ID: 36510111
[TBL] [Abstract][Full Text] [Related]
8. CRISPR takes on Huntington's disease.
Eisenstein M
Nature; 2018 May; 557(7707):S42-S43. PubMed ID: 29844549
[No Abstract] [Full Text] [Related]
9. Modern Genome Editing Technologies in Huntington's Disease Research.
Malankhanova TB; Malakhova AA; Medvedev SP; Zakian SM
J Huntingtons Dis; 2017; 6(1):19-31. PubMed ID: 28128770
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an In Vitro Model of Huntington's Disease.
Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28368337
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9-Mediated Genome Editing for Huntington's Disease.
Vachey G; Déglon N
Methods Mol Biol; 2018; 1780():463-481. PubMed ID: 29856031
[TBL] [Abstract][Full Text] [Related]
12. Limitations of Dual-Single Guide RNA CRISPR Strategies for the Treatment of Central Nervous System Genetic Disorders.
Duarte F; Vachey G; Caron NS; Sipion M; Rey M; Perrier AL; Hayden MR; Déglon N
Hum Gene Ther; 2023 Sep; 34(17-18):958-974. PubMed ID: 37658843
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9 novel therapeutic road for the treatment of neurodegenerative diseases.
Karimian A; Gorjizadeh N; Alemi F; Asemi Z; Azizian K; Soleimanpour J; Malakouti F; Targhazeh N; Majidinia M; Yousefi B
Life Sci; 2020 Oct; 259():118165. PubMed ID: 32735884
[TBL] [Abstract][Full Text] [Related]
14. How has CRISPR transformed therapeutic drug discovery?
Parker J
Biotechniques; 2023 Mar; 74(3):119-121. PubMed ID: 37083429
[TBL] [Abstract][Full Text] [Related]
15. Silencing of the Mutant Huntingtin Gene through CRISPR-Cas9 Improves the Mitochondrial Biomarkers in an In Vitro Model of Huntington's Disease.
Dunbar GL; Koneru S; Kolli N; Sandstrom M; Maiti P; Rossignol J
Cell Transplant; 2019 Apr; 28(4):460-463. PubMed ID: 30947515
[TBL] [Abstract][Full Text] [Related]
16. Allele-Specific Knockdown of Mutant Huntingtin Protein via Editing at Coding Region Single Nucleotide Polymorphism Heterozygosities.
Oikemus SR; Pfister EL; Sapp E; Chase KO; Kennington LA; Hudgens E; Miller R; Zhu LJ; Chaudhary A; Mick EO; Sena-Esteves M; Wolfe SA; DiFiglia M; Aronin N; Brodsky MH
Hum Gene Ther; 2022 Jan; 33(1-2):25-36. PubMed ID: 34376056
[TBL] [Abstract][Full Text] [Related]
17. CRISPR-Cas9 mediated genome editing of Huntington's disease neurospheres.
Han JY; Seo J; Choi Y; Im W; Ban JJ; Sung JJ
Mol Biol Rep; 2023 Mar; 50(3):2127-2136. PubMed ID: 36550260
[TBL] [Abstract][Full Text] [Related]
18. Advance genome editing technologies in the treatment of human diseases: CRISPR therapy (Review).
Alagoz M; Kherad N
Int J Mol Med; 2020 Aug; 46(2):521-534. PubMed ID: 32467995
[TBL] [Abstract][Full Text] [Related]
19. Next Generation Precision Medicine: CRISPR-mediated Genome Editing for the Treatment of Neurodegenerative Disorders.
Raikwar SP; Kikkeri NS; Sakuru R; Saeed D; Zahoor H; Premkumar K; Mentor S; Thangavel R; Dubova I; Ahmed ME; Selvakumar GP; Kempuraj D; Zaheer S; Iyer SS; Zaheer A
J Neuroimmune Pharmacol; 2019 Dec; 14(4):608-641. PubMed ID: 31011884
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
